Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.45 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.43 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | ITGAL | P20701 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19702028 | 0.93 | NOTUM (0.62) | NOTUMHRH3SETD2CCR5MCHR1 | |
| SCHEMBL19652215 | 0.89 | NOTUM (0.57) | NOTUMHRH3NPY5RPANK3CCR5 | |
| SCHEMBL19702022 | 0.85 | NOTUM (0.54) | NOTUMHRH3NPY5RCCR5ACACB | |
| SCHEMBL19658405 | 0.84 | PANK3 (0.47) | HRH3NPY5RPANK3MCHR1 | |
| SCHEMBL19658391 | 0.83 | NPY5R (0.60) | NOTUMNPY5RSETD2ACACB | |
| SCHEMBL19702020 | 0.82 | CCR5 (0.58) | NOTUMHRH3NPY5RCCR5PIK3CD | |
| SCHEMBL14321771 | 0.82 | NPY5R (0.61) | NPY5RSETD2MCHR1PIK3CD | |
| SCHEMBL26816763 | 0.81 | NOTUM (0.71) | NOTUMHRH3PANK3ACACBADAM10 | |
| SCHEMBL19702023 | 0.81 | NOTUM (0.49) | NOTUMHRH3NPY5RCCR5ACACB | |
| SCHEMBL19658738 | 0.81 | NPY5R (0.56) | NOTUMNPY5RMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | NOTUM 3221/4885HRH3 61/4885NPY5R 500/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | NOTUM 2215/4885HRH3 131/4885NPY5R 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.